Ackman, Icahn Discuss Reconciling Differences at Delivering Alpha
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- Wall St climbs as cooling inflation tempers Fed rate-hike concerns
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- HPE raises networking revenue outlook, secures $1.2B Vultr order
Aegis Comments on FDA 510(k) Approval of Bausch + Lomb's VICTUS (VRX)
July 17, 2014 9:56 AM EDTAegis Capital affirms Valeant Pharmaceuticals (NYSE: VRX) at Buy with a price target of $180 following news earlier that the company's wholly-owned subsidiary, Bausch + Lomb, has received 510(k) clearance from the FDA for the VICTUS Femtosecond Laser Platform for laser-assisted lens fragmentation during cataract surgery.
Analyst Ram Selvaraju commented, In our view, this approval demonstrates the growth potential of the Bausch + Lomb product portfolio and also showcases Valeant's continued commitment to launching new products in high-growth,... More
